HALLE (SAALE), Germany and Herlev, Denmark, 14 January 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) and Nordic Bioscience, announced today an agreement to collaborate […]
HALLE (SAALE), Germany, 7 January 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that the company is scheduled to attend the J.P. Morgan […]
HALLE (SAALE), Germany, 20 December 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that the company has been included in the AScX index as of […]
HALLE (SAALE), Germany, 28 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today its third quarter business update for the period ending September […]
HALLE (SAALE), Germany, 27 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today that management of Vivoryon Therapeutics will attend the CTAD […]
HALLE (SAALE), Germany, 21 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its third quarter financial results and a business update for the period […]
HALLE (SAALE), Germany, 4 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), announced today that the company is scheduled to attend and present at upcoming conferences […]
Vivoryon Therapeutics AG Successfully Completes a EUR 43 Million Capital Raise HALLE (SAALE), Germany, 24 October 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN: DE0007921835, […]
Vivoryon Therapeutics AG Launches Rights Offering to Fund its Phase 2b Clinical Development Program in Alzheimer’s Disease with Strong Commitments HALLE (SAALE), Germany, 08 October […]